Amniotic Fluid Embolism Treated With Inhaled Milrinone: A Case Report.

  title={Amniotic Fluid Embolism Treated With Inhaled Milrinone: A Case Report.},
  author={Frederick J. Baxter and Amanda Whippey},
  journal={A\&A Practice},
We present a patient with sudden cardiovascular collapse during cesarean delivery that was attributed to amniotic fluid embolism (AFE). The syndrome of AFE may be initiated by an anaphylactoid response to amniotic fluid in the maternal circulation that triggers the release of pulmonary vasoconstrictors, with transient pulmonary vasospasm, causing hemodynamic collapse and profound left ventricular failure. Milrinone, a pulmonary vasodilator used in the management of emergent right ventricular… 
1 Citations
Multiple drugs
  • Reactions Weekly
  • 2021


Amniotic Fluid Embolism Causing Catastrophic Pulmonary Vasoconstriction: Diagnosis by Transesophageal Echocardiogram and Treatment by Cardiopulmonary Bypass
Timely placement of transesophageal echocardiogram revealed catastrophic pulmonary vasoconstriction as the cause of circulatory collapse in a patient with amniotic fluid embolism, supporting the use of cardiopulmonary bypass as an effective intervention.
Rapid reversal of critical haemodynamic compromise with nitric oxide in a parturient with amniotic fluid embolism.
The patient was transferred to the intensive care unit with profound hypoxaemia, a high inotropic drug requirement and severe coagulopathy, and the introduction of nitric oxide at 40 ppm produced a dramatic improvement in her cardiorespiratory status.
Amniotic Fluid Embolism.
The pathophysiology involves an abnormal maternal response to fetal tissue exposure associated with breaches of the maternal-fetal physiologic barrier during parturition that involves activation of proinflammatory mediators similar to that seen with the classic systemic inflammatory response syndrome.
Amniotic fluid embolism: an evidence-based review.
An evidence-based review of information about [corrected] amniotic fluid embolism (AFE) found promising therapies include selective pulmonary vasodilators and recombinant activated factor VIIa.
The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism
A patient with massive pulmonary embolism for whom the addition of IAP to his therapy appeared to result in a transient improvement in pulmonary haemodynamics and gas exchange is described.
Nebulized Milrinone Use in a Pulmonary Hypertensive Crisis
A 42‐year‐old woman with acute decompensated idiopathic PAH who was given nebulized milrinone as a novel adjunctive therapy was given as salvage therapy for her acute PAH crisis and her PAH symptoms improved without compromising her mean arterial pressure and heart rate.
Inhaled Aerosolized Prostacyclin as a Selective Pulmonary Vasodilator for the Treatment of Severe Hypoxaemia
Inhaled aerosolized prostacyclin is a potent pulmonary vasodilator with little or no systemic hypotensive effect and would appear to be a viable alternative to inhaled nitric oxide.
Intratracheal Milrinone Bolus Administration During Acute Right Ventricular Dysfunction After Cardiopulmonary Bypass.
OBJECTIVE To evaluate intratracheal milrinone (tMil) administration for rapid treatment of right ventricular (RV) dysfunction as a novel route after cardiopulmonary bypass. DESIGN Retrospective
Preliminary experience with combined inhaled milrinone and prostacyclin in cardiac surgical patients with pulmonary hypertension.
Preemptive treatment of pulmonary hypertension with a combination of inhaled prostacyclin and milrinone before CPB was associated with a reduction in the severity of pulmonary pulmonary hypertension.
Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates
It is concluded that inhaled aerosolized milrinone for a short period selectively dilates the pulmonary vasculature in heart transplant candidates with elevated pulmonary arterial pressure, without producing systemic side effects.